With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.164148-92-9,tert-Butyl 6-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate,as a common compound, the synthetic route is as follows.
To a stirred solution of 2,4-dimethylimidazo[1,5-a]pyrimidine-8-carboxylic acid 3 (50 mg, 0.262 mmol), tert-butyl 6-amino-1,2,3,4-tetrahydroquinoline-2-carboxylate (72 mg, 0.288 mmol) and HATU (120 mg, 0.314 mmol) in DMF (1.0 mL) was added DIPEA (0.1 mL, 0.524 mmol), and the reaction mixture was stirred at room temperature for 16 h until the reaction was complete. The crude product was purified by prep-HPLC (MeCN/10 mM NH4HCO3) to give the Boc-protected form of the title compound as a white solid (62 mg, 56%). ES-MS m/z: 422 (M+H+). LC-MS Purity (254 nm): 96%; tR = 1.93 min.
164148-92-9, As the paragraph descriping shows that 164148-92-9 is playing an increasingly important role.
Reference£º
Patent; LYSOSOMAL THERAPEUTICS INC.; SKERLJ, Renato, T.; LANSBURY, Peter, T.; GOOD, Andrew, C.; BOURQUE, Elyse Marie, Josee; (134 pag.)WO2016/73889; (2016); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem